glp 1 agonists with cardiovascular benefit The effects of GLP-1 receptor beyond obesity and type 2 diabetes: An anti-atherosclerotic action GLP-1 receptor agonists for cardiovascular

a lot of celebrities were using it

Failure to follow these instructions for use could result in an over delivery or under delivery of insulin

Association between knee osteoarthritis and the risk of cardiovascular disease and the synergistic adverse effects of lack of exercise

Research is investigating its effects on non-alcoholic steatohepatitis (NASH), cardiovascular outcomes, and its role in reducing the risk of developing type 2 diabetes in individuals with prediabetes

Study done by van Eenige R, et al

But until now, there hasnt been any data from large epidemiologic studies. Results showed use of GLP-1 agonists compared with bupropion-naltrexone correlated with a 9.09 (95% CI, 1.25-66), 4.22 (95% CI, 1.02-17.4) and 3.67 (95% CI, 1.15-11.9) times higher risk for pancreatitis, bowel obstruction and gastroparesis, respectively